Role of low-molecular-weight heparins for the anticoagulant treatment of patients with prosthetic heart valves;Einsatz niedermolekularer heparine bei kunstklappenträgern

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 20, 2003, Pages 1129-1133

  Hering, Detlef ^a   Horstkotte, D ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CERTOPARIN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

ANTICOAGULANT THERAPY; HEART VALVE PROSTHESIS; HUMAN; REVIEW; RISK FACTOR; THROMBOEMBOLISM; TREATMENT INDICATION; BLEEDING; EMBOLISM; THROMBOSIS;

ANTICOAGULANTS; EMBOLISM; HEART VALVE PROSTHESIS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RISK FACTORS; THROMBOSIS;

EID: 0037507088     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39258     Document Type: Review

References (36)

1. Aguilar D, Goldhaber SZ. Clinical uses of low-molecular-weight heparins. Chest 1999; 115: 1418-1423
2. Arnaout MS, Kazma H, Khalil A et al. Is there a safe anticoagulation protocol for pregnant women with prosthetic valves? Clin Exp Obstet Gynecol 1998; 25: 101-104
3. Behrendt P, Schwartzkopff B, Perings S, Gerhardt A, Zotz RB, Strauer BE. Successful thrombolysis of St. Jude Medical aortic prosthesis with tissue-type plasminogen activator in a pregnant woman: a case report. Cardiol Rev 2002; 10: 349-353
4. Berdagué P, Boneu B, Soula P, Dambrin C, Vernhet JC, Cérène A. Usefulness of low-molecular-weight heparins during post-operative period in mitral mechanical valve replacement: clinical ischaemic and haemorrhagic complications in 110 cases (abstract). Eur Heart J 1998; 19 (Suppl); 534
5. Berndt N, Khan I, Gallo R. A complication in anticoagulation using low-molecular weight heparin in a patient with a mechanical valve prosthesis. A case report. J Heart Valve Dis 2000; 9: 844-846
6. Bonow RO, Carabello B, Jr. de Leon AC et al. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of patients with valvular heart disease). J Am Coll Cardiol 1998; 32: 1468-1588
7. Chan WS, Anand S, Ginsberg JC. Anticoagulation of pregnant women with mechanical heart valves. A systematic review of the literature. Arch Intern Med 2000; 160: 191-196
8. Cohen M. The role of low-molecular-weight heparin in the management of acute coronary syndromes. Curr Opin Cardiol 2001; 16: 384-389
9. Ferreira IJ, Dos L, Tornos MP, Nicolau I, Soler J. Is low-molecular-weight heparin a safe alternative to unfractioned heparin in patients with prosthetic mechanical heart valves who must interrupt anti-thrombotic therapy? (abstract). Eur Heart J 2000; 21 (Suppl); 301
10. Galla JM, Fuhs BE. Outpatient anticoagulation protocol for mechanical valve recipients undergoing non-cardiac surgery (abstract). J Am Coll Cardiol 2000; 35 (Suppl A); 531
11. Gohlke-Bärwolf C. Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery. Heart 2000; 84: 567-572
12. Gohlke-Bärwolf C. Antikoagulation in graviditate und post partum bei Vitien, Thrombosen oder Vorhofflimmern: fötale Bedrohung versus maternelle Thromboembolie. Z Kardiol 2001; 90 (Suppl 4); 49-56
13. Gohlke-Bärwolf C, Acar J, Oakley C et al. Guidelines for prevention of thromboembolic events in valvular heart disease. Eur Heart J 1995; 16: 1320-1330
14. Harenberg J, Huhle G, Piazolo L, Giese C, Heene DL. Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin. Semin Thromb Hemost 1997; 23: 167-172
15. Harenberg J, Schwarz F, Dietz R, Leber G, Zimmermann R, Kübler W. Antikoagulation mit niedermolekularem Heparin bei Patienten mit prothetischem Herzklappenersatz. Z Kardiol 1987; 76: 284-288
16. Hirsh J, Bates SM. The emerging role of low-molecular-weight heparin in cardiovascular medicine. Prog Cardiovasc Dis 2000; 42: 235-246
17. Idir M, Madonna F, Roudaut R. Collapse and massive pulmonary edema secondary to thrombosis of a mitral mechanical heart valve prosthesis during low-molecular weight heparin therapy. J Heart Valve Dis 1999; 8: 303-304
18. Kemkes-Matthes B. Veränderungen des Gerinnungssystems in der Schwangerschaft. Z Kardiol 2001; 90 (Suppl 4); 45-48
19. Koopman MMW, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. New Engl J Med 1996; 334: 682-687
20. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681
21. Lev-Ran O, Kramer A, Gurevitch J, Shapira I, Mohr R. Low-molecular-weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg 2000; 69: 264-266
22. Leyh RG, Fischer S, Ruhparwar A, Haverich A. Antikoagulation bei schwangeren Frauen nach künstlichem Herzklappenersatz: lst niedermolekulares Heparin eine Alternative? Z Kardiol 2002; 91: 297-303
23. Lindhoff-Last E, Schinzel H, Erbe M, Schächinger V, Bauersachs R. Antikoagulation in der Schwangerschaft bei mechanischem Herzklappenersatz. Z Kardiol 2001; 90 (Suppl 6); 125-130
24. Mahesh B, Evans S, Bryan AJ. Failure of low molecular-weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and a review of options for anticoagulation. J Heart Valve Dis 2002; 11: 745-750
25. Montalescot G, Polle V, Collet JP et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000; 101: 1083-1086
26. Oles D, Berryessa R, Campbell K, Bhatti MA. Emergency redo mitral valve replacement in a 27-year-old pregnant female with a clotted prosthetic mitral valve, preoperative fetal demise and postoperative ventricular assist device: a case report. Perfusion 2001; 16: 159-164
27. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87: 182-186
28. Rowan JA, Mcfowan LME, Raudkivi PJ, North RA. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol 2001; 185: 633-637
29. Schreiber C, Augustin N, Holper K, Lange R. Akute Thrombose einer mechanischen Herzklappe durch inadäquate Antikoagulation mit niedermolekularem Heparin. Herz 2001; 26: 482-484
30. Schröder F, Weiss T. Niedermolekulare Heparine. Dtsch Med Wochenschr 2002; 127: 1645-1647
31. Shapira Y, Sagie A, Battler A. Low-molecular-weight heparin for the treatment of patients with mechanical heart valves. Clin Cardiol 2002; 25: 323-327
32. Shapira Y, Vaturi M, Sagie A. Anticoagulant management of patients with mechanical prosthetic valves undergoing non-cardiac surgery: indications and unresolved issues. J Heart Valve Dis 2001; 10: 380-387
33. Simonneau G, Sors H, Charbonnier B et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. New Engl J Med 1997; 337: 663-669
34. Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84: 478-480
35. Stein PD, Alpert JS, Dalen JE, Horstkotte D, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1998; 114 (Suppl); 602S-610S
36. Tinmouth AH, Morrow BH, Cruickshank MK, Moore PM, Kovacs MJ. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother 2001; 35: 669-674